INVO Fertility, Inc. is a healthcare company specializing in fertility and assisted reproductive technology, operating fertility clinics and developing the INVOcell device for natural fertilization.

# Company Summary: INVO Fertility, Inc.

## Overview
- **Business Focus:** Healthcare services specializing in fertility and assisted reproductive technology (ART).
- **Core Strategy:** Building, acquiring, and operating fertility clinics, including "INVO Centers" focusing on intravaginal culture (IVC) procedure enabled by the INVOcell® device, and profitable IVF clinics.
- **Main Product:** INVOcell®, an intravaginal culture device allowing fertilization and early embryo development within the woman’s body, potentially reducing costs and increasing accessibility compared to traditional IVF.

## Operations
- **Fertility Clinics:**
  - As of the report, operates **2 INVO Centers** and **1 IVF clinic** in the United States.
  - Acquired **Wisconsin Fertility Institute (WFI)** in August 2023, which is a profitable IVF clinic that became a major revenue and cash flow source.
  - Developed joint ventures in Birmingham, Alabama and Atlanta, Georgia to expand use of INVOcell and increase patient access.
- **NAYA Therapeutics Segment:**
  - Acquired in October 2024 to diversify into oncology and autoimmune biotech markets.
  - Recent strategic decision to divest and focus exclusively on fertility.
  - Will retain a minority stake in NAYA and intends to monetize it in the future.

## Technologies
- **INVOcell® Device:**
  - Medical device enabling natural fertilization and early embryo development in vivo.
  - Cleared by FDA in November 2015.
  - Expanded FDA use in June 2023 for a 5-day incubation.
  - Supports a more affordable and natural fertility treatment alternative.
- **Market Position:** The company believes the INVOcell procedure has comparable pregnancy and live birth rates to IVF but at a lower cost.
  
## Employees and Customers
- **Employees (as of December 31, 2024):** 
  - 8 full-time employees directly employed by INVO.
  - Additional 20 full-time and 4 part-time employees across the clinics.
  - 5 full-time employees for NAYA Therapeutics.
- **Customer Base:** 
  - Operates clinics that have internal patient referral systems mainly via OBGYNs and word-of-mouth.
  - As of April 29, 2025, **1,066,065 shares of common stock** outstanding.
  
## Financials
- **Market Capitalization:** 
  - As of the last measurement (June 30, 2024), approximately **$7,381,118**, based on a stock price of $10.08.
- **Revenue and Income:**
  - The company had an **accumulated net loss of $67.2 million** from inception (2007) through December 31, 2024.
  - The acquisition of WFI tripled annual revenue (specific revenue figures not provided).
  - Completed a **public offering in January 2025** raising approximately **$9.5 million** before expenses.
  
## Market Opportunity
- Operates in a large, growing global ART market with unmet demand due to capacity and cost barriers.
- U.S. fertility market:
  - Estimated 6.7 million women with impaired fertility.
  - Around 435,000 IVF cycles performed annually across roughly 500 clinics.
- The company aims to expand access through new clinics and acquisition of existing profitable practices.

## Strategic Focus
- Transitioned from device distribution to clinic operations.
- Opening additional INVO Centers to serve underserved markets.
- Will rest solely on fertility business following recent decisions to divest biotech segment.

---

*This summary reflects the company's current operations, products, employee count, and financial status as detailed in the provided document.*

INVO Bioscience, Inc. is a publicly traded company focused on innovative reproductive healthcare solutions, particularly through its product INVOcell for enhancing assisted reproductive technology success rates.

# INVO Bioscience, Inc. Overview

## Company Description
INVO Bioscience, Inc. is a publicly traded company specializing in reproductive healthcare and reproductive technologies. The company is focused on providing innovative solutions to enhance the success rates of assisted reproductive technologies (ART) for patients facing challenges with fertility.

### Core Product
- **INVOcell®**: INVO’s primary product is INVOcell, a medical device that allows for in vivo fertilization and culture of human embryos within a woman’s body. This approach aims to address the high costs and complexities associated with conventional laboratory-based in vitro fertilization (IVF).

## Market and Customers
- **Target Market**: The company targets couples experiencing infertility, as well as fertility clinics that offer ART services.
- **Customer Base**: While specific customer count is not disclosed, the company serves numerous fertility clinics and individual patients as part of its market offering. 

## Operations and Workforce
- **Employees**: INVO Bioscience currently has a small workforce, with executive roles filled by experienced professionals in finance, operations, marketing, and development.
  
## Financial Overview
- **Revenue**: As of the latest fiscal year ending December 31, 2023, the company reported total revenues of approximately $2.8 million.
- **Net Income**: INVO reported a net loss for the year ending December 31, 2023, amounting to about $(8.03) million, which reflects the investments in expanding their market reach and increasing operational capabilities.

## Growth Strategy
INVO BioScience is concentrating on expanding its presence in the fertility market through various strategies:
- **Increasing Distribution**: INVO aims to expand its distribution network, thereby improving access to its INVOcell product in more fertility clinics.
- **Marketing Initiatives**: The company is investing in marketing efforts to promote awareness and education around its innovative reproductive technology solutions.

## Summary
INVO Bioscience, Inc. is an innovative player in the reproductive healthcare industry, driven by its flagship product, INVOcell. Despite operating at a loss, the company seeks growth through expanded market access and enhanced customer engagement within the fertility sector.

INVO Fertility, Inc.

10-K / April 30, 2025

10-K / April 29, 2024

10-K / April 30, 2025

Company Summary: INVO Fertility, Inc.

Overview

Operations

Technologies

Employees and Customers

Financials

Market Opportunity

Strategic Focus